유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastic lyfjum - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - Æxlishemjandi lyf - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 40 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 20 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 10 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - esomeprazolum - magasýruþolin tafla - 40 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - esomeprazolum magnesíum díhýdrat - magasýruþolið hart hylki - 20 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - esomeprazolum magnesíum díhýdrat - magasýruþolið hart hylki - 40 mg